Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines.
Livingston
P O
PO
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001500:BCG Vaccine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000627:therapeutic use; D004311:Double-Blind Method; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D008545:Melanoma / Q000276:immunology*; D016019:Survival Analysis
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D005732:Gangliosides; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D003520:Cyclophosphamide